Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Suwida Tangtrakultham"'
Publikováno v:
Pharmaceutical Sciences Asia, Vol 49, Iss 4, Pp 312-322 (2022)
Chloroquine (CQ) efficacy was shown in some coronavirus disease 2019 (COVID-19) adult clinical studies. However, its data in children is still limited. Therefore, this study aims to assess the suitability of the dosage regimens from the literature an
Externí odkaz:
https://doaj.org/article/311eec0062d14542ad26a65b0f64e167
Publikováno v:
Pharmaceutical Sciences Asia, Vol 49, Iss 1, Pp 22-33 (2022)
Hydroxychloroquine may be used to treat COVID-19 infections when remdesivir is unavailable. There is currently no hydroxychloroquine dosage regimen for pediatrics with COVID-19 infections. We aimed to determine the optimal dosage regimen needed to ra
Externí odkaz:
https://doaj.org/article/db60c2c9ff734bdfafdfa247250fb635
Autor:
Suwida Tangtrakultham, Jantana Houngsaitong, Korbtham Sathirakul, Wichit Nosoongnoen, Supatat Chumnumwat, Preecha Montakantikul
Publikováno v:
Pharmaceutical Sciences Asia. 50:120-130
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1fcbdf94039a7cbc0c7da686348c3f66
https://doi.org/10.29090/psa.2023.02.22.368
https://doi.org/10.29090/psa.2023.02.22.368
Autor:
Nattapong Tidwong, Baralee Punyawudho, Pannee Leelawattanachai, Suwida Tangtrakultham, Pitchaya Dilokpattanamongkol, Taniya Paiboonvong, Supatat Chumnumwat, Preecha Montakantikul
Publikováno v:
Pharmaceutical Sciences Asia. 48:291-299
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ef16ded7b64f6a56630b79534b7ada73
https://doi.org/10.29090/psa.2021.03.20.197
https://doi.org/10.29090/psa.2021.03.20.197
Autor:
Ei Ei Win, Khaing Win Htun, Pramote Tragulpiankit, Suwida Tangtrakultham, Preecha Montakantikul
Publikováno v:
Infection and Drug Resistance.
Ei Ei Win,1 Khaing Win Htun,2 Pramote Tragulpiankit,1 Suwida Tangtrakultham,1 Preecha Montakantikul1 1Division of Clinical Pharmacy, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, 10400, Thailand; 2Right Laboratory and Heal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a113fd974fbc470145530570a1245af3
https://www.dovepress.com/the-evaluation-of-meropenem-dosing-regimens-against-esbl-producing-esc-peer-reviewed-fulltext-article-IDR
https://www.dovepress.com/the-evaluation-of-meropenem-dosing-regimens-against-esbl-producing-esc-peer-reviewed-fulltext-article-IDR
Autor:
Ei Ei, Win, Khaing Win, Htun, Pramote, Tragulpiankit, Suwida, Tangtrakultham, Preecha, Montakantikul
Publikováno v:
Infection and drug resistance. 15
To evaluate the optimal dosing regimens of meropenem against extended-spectrum beta-lactamase-producingThe MCS was performed using the minimum inhibitory concentration (MIC) data from Right Laboratory and Health Screen in Naypyitaw, Myanmar, as well
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::e17451b580a52a06455adafb30d05a92
https://pubmed.ncbi.nlm.nih.gov/35177911
https://pubmed.ncbi.nlm.nih.gov/35177911